Scientists at the L...This is the first paper based solely on theoretical yet practically p...All cells of an organism originate from embryonic stem cells which di...The techniques for cell programming are still in their infancy. Stem c...

Scientists at the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg have developed a model that makes predictions from which differentiated cells for instance skin cells can be very efficiently changed into completely different cell types such as nerve cells, for example. This can be done entirely without stem cells. These computer-based instructions for reprogramming cells are of huge significance for regenerative medicine. The LCSB researchers present their results today in the prestigious scientific journal Stem Cells.

This is the first paper based solely on theoretical, yet practically proven, results of computational biology to be published in this journal. (DOI: 10.1002/stem.1473).

All cells of an organism originate from embryonic stem cells, which divide and increasingly differentiate as they do so. The ensuing tissue cells remain in a stable state; a skin cell does not spontaneously change into a nerve cell or heart muscle cell. "Yet the medical profession is greatly interested in such changes, nonetheless. They could yield new options for regenerative medicine," says Professor Antonio del Sol, head of the Computational Biology group at LCSB. The applications could be of enormous benefit: When nerve tissue becomes diseased, for example, then doctors could take healthy cells from the patient's own skin. They could then reprogram these to develop into nerve cells. These healthy nerve cells would then be implanted into the diseased tissue or even replace it entirely. This would treat, and ideally heal, diseases such as Parkinson's disease.

The techniques for cell programming are still in their infancy. Stem cell researchers Shinya Yamanaka and John Burdon received the Nobel Prize for converting differentiated body cells back into stem cells only last year. The first successful direct conversion of skin cells to nerve cells in the lab was in 2010. Biologists add refined cocktails of molecules, i.e. growth factors, to the cell cultures in a certain order. This allows them to control the genetic activity in the conversion process. However, this method so far has been largely guided by educated trial and error.

Variable jumping between different cell lines is possible

Now, the LCSB researchers have replaced trial and error with computer calculations, as computer scientist and PhD student at LCSB Isaac Crespo explains: "Our theoretical model first queries databases where vast amounts of information on gene actions and their effects are stored and then identifies the genes that maintain the stability of differentiated cells. Working from the appropriate records, the model suggests which genes in the starting cells need to be switched on and off again, and when, in order to change them into a different cell type."

"Our predictions have proved very accurate in the lab," says Professor del Sol: "And it turns out it makes no difference at all how similar the cells are. The models work equally well for cell lines that have only just branched off from one another as for those that are already very far apart." Prof. del Sol's and Crespo's model thus allows highly variable jumping between very different cell types without taking a detour via stem cells.

The biologists and medical scientists still have their lab work cut out for them: They have to identify all the growth factors that initiate the respective genetic activities in the correct, predicted order.

(Date:11/19/2016)... Securus Technologies, a leading provider of civil and criminal ... monitoring, announced today that it has offered a challenge ... technology judge determine who has the largest and best ... platform, and the best customer service. "ICSolutions ... we do – which clearly is not the case ...

(Date:12/7/2016)... Diego (PRWEB) , ... December 07, 2016 , ... ... data from its phase I/II dose escalation and expansion clinical trial for its ... in Vienna, Austria. The purpose of the trial was to determine the safety, ...

(Date:12/7/2016)... , Dec. 7, 2016 Neogen Corporation ... named Dr. Dan Kephart as its chief ... Kephart will assume his responsibilities at Neogen effective Jan. ... development director for the agribusiness unit of Thermo Fisher ... development at Life Technologies. His extensive industry experience also ...

(Date:12/7/2016)... 2016 Nordion, a standalone business of Sterigenics ... today,s award by the United States Department of ... the Phase II cooperative agreement funding to GA ... University of Missouri Research Reactor Center (MURR ® ... establishment of a new, reliable supply of molybdenum ...

(Date:12/7/2016)... 7, 2016 Vyriad Inc. announced today the appointment ... Board of Directors. "We are delighted to ... business and develop our oncolytic viruses as the next ... Stephen Russell , MD, PhD, CEO of Vyriad. "Al ... vision and passion for making a difference for cancer ...